|
Increase in CD4 Cell Counts and CD4:CD8 Ratio After 3 scIL-3 Cycles. |
||
| scIL-2 Dosage |
Change in CD4 Number |
Increase in Ratio* |
|
|
||
| 7.5 MIU(n = 4) |
863 ± 434 |
0.88 ± 0.15 |
| 1.5 MIU(n = 5) |
554 ± 458 |
0.53 ± 0.09 |
| Control (n = 3) |
442 ± 284 |
0.23 ± 0.14 |
|
* Day 65 in treated and week 24 in controls. All different from each other (p = < 0.01). All patients increased their CD4:CD8 ratio, with the high dose IL-2 patients responding best. There is one missing endpoint in the high dosage at Day 65 and one in the group that received no IL-2 at 24 weeks. | ||
Lewis et al. Journal of Translational Medicine 2007 5:9 doi:10.1186/1479-5876-5-9 |
||